Bio-Techne Corporation

11/05/2024 | Press release | Distributed by Public on 11/05/2024 15:47

Statement of Changes in Beneficial Ownership - Form 4

Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
(Print or Type Responses)
1. Name and Address of Reporting Person *
Hippel James
2. Issuer Name and Ticker or Trading Symbol
BIO-TECHNE Corp [TECH] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
CFO
(Last) (First) (Middle)
614 MCKINLEY PLACE NE 		3. Date of Earliest Transaction (Month/Day/Year)
11/01/2024
(Street)
MINNEAPOLIS, MN 55413 		4. If Amendment, Date Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City) (State) (Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 		7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/01/2024 M 13,159 A $ 0 113,085 D
Common Stock 11/01/2024 F 6,475 D $75.31 106,610 D
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 		6. Date Exercisable and Expiration Date
(Month/Day/Year) 		7. Title and Amount of Underlying Securities
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4) 		10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 		11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $31.26 (1) 08/09/2024 Common Stock 53,867 53,867 D
Stock Options (Right to Buy) $44.33 (1) 08/08/2025 Common Stock 168,620 168,620 D
Stock Options (Right to Buy) $47.6 (1) 08/07/2026 Common Stock 186,068 186,068 D
Stock Options (Right to Buy) $66.97 (1) 08/05/2027 Common Stock 167,328 167,328 D
Stock Options (Right to Buy) $120.46 (2) 08/06/2028 Common Stock 40,536 40,536 D
Performance Restricted Stock Units (3) (4) (4) Common Stock 10,912 10,912 D
Performance Stock Options (Right to Buy) $94.52 (4) 08/15/2029 Common Stock 33,916 33,916 D
Stock Options (Right to Buy) $94.52 (5) 08/15/2029 Common Stock 45,220 45,220 D
Performance Restricted Stock Units (3) (6) (6) Common Stock 13,865 13,865 D
Performance Stock Options (Right to Buy) $84.61 (6) 08/15/2030 Common Stock 37,314 37,314 D
Stock Options (Right to Buy) $84.61 (7) 08/15/2030 Common Stock 45,923 45,923 D
Restricted Stock Units (3) 11/01/2024 M 13,159 (8) (8) Common Stock 13,159 $ 0 13,159 D
Performance Restricted Stock Units (3) (9) (9) Common Stock 24,062 24,062 D
Restricted Stock Units (3) (10) (10) Common Stock 12,031 12,031 D
Stock Options (Right to Buy) $74.91 (11) 08/15/2034 Common Stock 32,417 32,417 D
Restricted Stock Units (3) 11/01/2024 A 34,634 (12) (12) Common Stock 34,634 $ 0 34,634 D

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Hippel James
614 MCKINLEY PLACE NE
MINNEAPOLIS, MN 55413 		CFO

Signatures

/s/ Andrew Nick as Attorney-in-Fact for James Hippel pursuant to Power of Attorney previously filed 11/05/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Fully exercisable.
(2) Options to purchase 10,134 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.
(3) Each restricted stock unit represents a contingent right to receive one share of Bio-Techne Corporation common stock.
(4) Vests in full or in part on 8/15/2025 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(5) Options to purchase 11,305 shares vest on each of 8/15/2023, 8/15/2024, 8/15/2025 and 8/15/2026.
(6) Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(7) Options to purchase 11,481 shares vest on each of 8/15/2024, 8/15/2025 and 8/15/2027, and options to purchase 11,480 shares vest on 8/15/2026.
(8) On 11/1/2024, the Board of Directors certified vesting of ____ performance RSUs. The remaining 13,159 restricted stock units vest on 11/1/2025.
(9) Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
(10) 4,010 restricted stock units vest on each of 8/15/2025 and 8/15/2026, and 4,011 restricted stock units vest on 8/15/2027.
(11) Options to purchase 8,104 shares vest on each of 8/15/2025, 8/15/2026 and 8/15/2027, and options to purchase 8,105 shares vest on 8/15/2028.
(12) 11,545 restricted stock units vest on each of 11/1/2025 and 11/1/2026; and 11,544 restricted stock units vest on 11/1/2027.
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.